These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28902717)

  • 1. New approaches to address dyslipidemia.
    Parhofer KG
    Curr Opin Lipidol; 2017 Dec; 28(6):452-457. PubMed ID: 28902717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery Approaches for Novel Dyslipidemia Drugs.
    Maqbool F; Safavi M; Bahadar H; Rahimifard M; Niaz K; Abdollahi M
    Curr Drug Discov Technol; 2015; 12(2):90-116. PubMed ID: 26135857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-density lipoprotein lowering in 2013 by nonstatin agents: the discovery and development of promising novel targeted therapies.
    Kohli P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):199-210. PubMed ID: 23580658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antilipidemic Drug Therapy Today and in the Future.
    Kramer W
    Handb Exp Pharmacol; 2016; 233():373-435. PubMed ID: 26330256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.
    Khera AV; Rader DJ
    Trends Cardiovasc Med; 2009 Aug; 19(6):195-201. PubMed ID: 20211435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PERSONALIZED APPROACH TO LIPID-LOWERING THERAPY].
    Scheen AJ; Descamps OS
    Rev Med Liege; 2015; 70(5-6):292-8. PubMed ID: 26285455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current and future trends in the treatment of dyslipidemias].
    Vrablík M
    Vnitr Lek; 2019; 65(10):643-650. PubMed ID: 31906686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia management update.
    Chang Y; Robidoux J
    Curr Opin Pharmacol; 2017 Apr; 33():47-55. PubMed ID: 28527325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The new lipid-lowering drugs: focus on monoclonal antibodies].
    Borghi C; Cimminiello C
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):14S-21. PubMed ID: 27312019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New oral agents for treating dyslipidemia.
    Gryn SE; Hegele RA
    Curr Opin Lipidol; 2016 Dec; 27(6):579-584. PubMed ID: 27676196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Lowering Therapy and Circulating PCSK9 Concentration.
    Nozue T
    J Atheroscler Thromb; 2017 Sep; 24(9):895-907. PubMed ID: 28804094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemias in clinical practice.
    Castro Cabezas M; Burggraaf B; Klop B
    Clin Chim Acta; 2018 Dec; 487():117-125. PubMed ID: 30201369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.